MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
+0.05 (+0.40%)
收市:04:00PM EDT
買盤12.31 x 800
賣出價12.76 x 900
今日波幅12.45 - 12.56
52 週波幅3.00 - 13.66
Beta 值 (5 年,每月)1.80
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-0.12
業績公佈日2023年8月02日 - 2023年8月07日
遠期股息及收益率無 (無)
1 年預測目標價4.00
  • Insider Monkey

    12 Best Performing Biotech Stocks in 2022

    In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]

  • Benzinga

    Why Merrimack Shares Are Surging Over 200% Today?

    Ipsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint. The combination therapy demonstrated a clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Progression-free survival (PFS) also showed significant improvement ov

  • Benzinga

    Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure

    Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabilit